Does Tremfya Cause Cough?
Tremfya (guselkumab), an IL-23 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease, lists upper respiratory infections as a common side effect in clinical trials, which can include cough. Cough itself appears as an uncommon adverse reaction (affecting 1-10% of patients) in product labeling from Janssen. In pooled safety data from psoriasis studies, cough occurred in 1.6% of Tremfya patients versus 0.7% on placebo.[1][2]
How Common Is Cough with Tremfya?
Clinical trials show cough rates around 1-3% across indications:
- Psoriasis (VOYAGE 1/2 trials): 1.6-2.1% incidence.
- Psoriatic arthritis (DISCOVER trials): Up to 2.5%.
- Crohn's disease (Phase 3 data): Similar low single-digit rates.
These are higher than placebo but lower than infection-related symptoms like nasopharyngitis (10-14%). Post-marketing reports note cough occasionally, often tied to respiratory infections rather than direct causation.[1][3]
What Do Patients Report About Cough on Tremfya?
Real-world data from patient forums and FDA adverse event reports (FAERS) show cough complaints in a small subset, often mild and transient. About 0.5-1% of FAERS cases for Tremfya mention cough, sometimes with dyspnea or bronchitis. Users on Drugs.com rate Tremfya 7.2/10 overall, with cough rarely highlighted in reviews—most focus on injection-site reactions or fatigue instead.[4][5]
When Should You Worry About Cough on Tremfya?
Most cases resolve without intervention, but watch for signs of serious infection (e.g., persistent cough with fever, shortness of breath), as Tremfya increases infection risk by suppressing immune responses. Label warns of heightened upper respiratory tract infection odds (14% vs. 10% placebo). Consult a doctor if cough lasts over a week or worsens—discontinuation is rare but possible.[1][2]
How Does Tremfya's Cough Risk Compare to Other Biologics?
| Drug | Cough Incidence (Trials) | Notes |
|------|---------------------------|-------|
| Tremfya | 1-3% | Low; infection-linked |
| Stelara (ustekinumab) | 2-4% | Similar IL pathway |
| Skyrizi (risankizumab) | 1-2% | Closest competitor, marginally lower |
| Humira (adalimumab) | 3-6% | Higher with TNF inhibition |
| Cosentyx (secukinumab) | 2-5% | IL-17 related, more URI overall |
Tremfya has one of the lowest profiles among IL inhibitors.[1][3][6]
Managing Cough While on Tremfya
Treat symptomatically with hydration, lozenges, or OTC expectorants unless contraindicated. Avoid if active infection; doctors may pause dosing. No specific Tremfya-cough interactions noted with common cough meds.[2]
[1]: Tremfya Prescribing Information (Janssen)
[2]: FDA Label for Guselkumab
[3]: Drugs.com - Tremfya Side Effects
[4]: FAERS Public Dashboard (FDA)
[5]: Drugs.com User Reviews
[6]: Skyrizi Prescribing Information (AbbVie)